Cancer.Net Associate Editor: Lymphoma
University of Virginia Health System, Charlottesville, VA
Dr. Michael E. Williams is the Byrd S. Leavell Professor of Medicine and Professor of Pathology at the University of Virginia School of Medicine. He serves as Chief of the Hematology/Oncology Division, Physician Lead for the Cancer Service Line, and Associate Director for Clinical Affairs in the UVA Cancer Center.
Dr. Williams received his medical degree from the University of Cincinnati College of Medicine and a Master of Science from the Harvard School of Public Health. He completed his medical residency, chief residency, and fellowship in hematology/oncology at the UVA Health System.
Dr. Williams’ clinical and research interests are in advancing treatment approaches for non-Hodgkin lymphomas, mantle cell lymphoma, and CLL, including targeted therapeutics and immunotherapy. He serves on the scientific advisory board of the Lymphoma Research Foundation, is a member of the European Mantle Cell Lymphoma Network and is vice-chair of the Eastern Cooperative Oncology Group (ECOG) Lymphoma Core Committee. He is past Chair of the Hematology Subspecialty Board of the American Board of Internal Medicine, where he also served as an ABIM Council Member.
He participates regularly in national and international programs devoted to education and research in lymphoma and hematologic malignancies.
Disclosures: In the past two years, Dr. Williams has served as a consultant and/or advisor for Abbvie, Astra-Zeneca, Celgene, Gilead, Janssen, Juno, Kite, Sandoz, Seattle Genetics, TG Therapeutics and Verastem, and his institution has received research funding from Allos, Celgene, Gilead, Janssen, Novartis, Pharmacyclics and Takeda.
Last updated: August 2018